Quoin Pharmaceuticals (QNRX) Projected to Post Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

Quoin Pharmaceuticals Trading Down 5.6 %

Shares of NASDAQ:QNRX opened at $0.29 on Tuesday. The stock has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $0.57. Quoin Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $1.57. The stock has a market capitalization of $1.48 million, a price-to-earnings ratio of -0.07 and a beta of 1.82.

Insider Transactions at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, Director Anthony James Culverwell bought 100,000 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, for a total transaction of $45,000.00. Following the purchase, the director now owns 100,317 shares in the company, valued at approximately $45,142.65. This trade represents a 31,545.74 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gordon Dunn bought 122,221 shares of Quoin Pharmaceuticals stock in a transaction on Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, with a total value of $54,999.45. Following the acquisition, the chief financial officer now owns 151,077 shares in the company, valued at approximately $67,984.65. This represents a 423.55 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 777,777 shares of company stock valued at $350,000 in the last quarter. 3.70% of the stock is owned by insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.